Category survey

Understanding the molecular functions of progranulin and granulin in FTLD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Role of phosphoinositides in neuronal membrane traffic and neurodegeneration Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Gamma-Secretase and Myelin: A Paradigm Shift in Brain Disorders Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Determinants of Neurodegenerative Decline in Primary Progressive Aphasia Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Robust rare event simulation for protein folding and disease-related aggregation Investments > €500k United States of America Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

Klotho and Neurodegenerative Disease Investments > €500k United States of America Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

The regulation of beta-amyloid sensitivity and Alzheimers related impairments by PP2A Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Role of Tau Cleavage in Tauopathy Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Cholesterol Metabolizing P450s; structure and function Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Tau-mediated regulation of axonal transport Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Silencing C9or72 with rAAV Mediated RNAi Investments > €500k United States of America Alzheimer’s disease & other dementias|Motor neurone diseases 2016    

Preclinical Diagnostic Imaging of Amyloid Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

GGGGCC hexanucleotide repeat expansions in neurodegenerative disease Investments > €500k United States of America Alzheimer’s disease & other dementias|Motor neurone diseases 2016    

Circadian dysfunction and GSK3 in neurodegenerative disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Biological and Pathological Interactions between Tau and LRRK2 Investments > €500k United States of America Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders 2016    

Defining the role of FUS phosphorylation in neurodegeneration Investments > €500k United States of America Alzheimer’s disease & other dementias|Motor neurone diseases 2016    

Endocannabinoids in Neurodegenerative Diseases Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

PERK as a central mediator of neurotoxicity in tauopathies Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Structures and Propagation of Pathologically Relevant Amyloids in Alzheimers. Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Imaging neuronal and capillary dysfunction deep in the rodent brain in vivo using 1700 nm Optical Coherence Microscopy and tracer-based kinetics Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Vascular breakdown in Alzheimers Disease with cerebrovascular disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Memory processing after neuron loss in the entorhinal cortex and hippocampus Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

A Drosophila model for studying mechanisms of Gauchers disease and synucleinopathies Investments > €500k United States of America Motor neurone diseases|Neurodegenerative disease in general|Parkinson’s disease & PD-related disorders 2016    

The Role of Perlecan Domain V in Vascular Dementia Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Orb2 a functional amyloid in long-term memory: Its structure and how it forms Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

The Role of C9ORF72 Protein Function in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Investments > €500k United States of America Alzheimer’s disease & other dementias|Motor neurone diseases 2016    

White matter hypoxia in a novel model of MMP-mediated inflammation in SHR/SP Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Mimicry of Amyloid Oligomers Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

General Anesthesia and Alzheimers Disease Neuropathogenesis Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

The role of inflammasome signaling in tauopathies Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Design of antibody fragments specific for amyloidogenic aggregates Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Excessive Lysosomal Exocytosis Triggers Pathogenic Mechanisms in Sialidosis Mice Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Dissecting the Toxicity of Glial and Neuronal Expression of APP in the Brain Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

The Impact Of Surgery-Induced Neuroinflammation On Tau Pathology And Function Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Targeted gene transfer across specific synapse types Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Development of an information-rich assay for C9ORF72 as a test for ALS and FTD Investments > €500k United States of America Alzheimer’s disease & other dementias|Motor neurone diseases 2016    

Propagation of tauopathy: role of degeneration and impact of immunotherapy Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Theoretical and computational modeling of amyloid aggregation Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Role of BACE in the pathogenesis of Alzheimers disease after head trauma Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

NOVEL BIFUNCTIONAL CHEMICAL AGENTS AS THERANOSTIC TOOLS FOR AMYLOID DISEASES Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Molecular aspects of copper and zinc binding to the prion protein Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

RAGE and mitochondrial degeneration in diabetes Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Using RNA signatures for therapy development in neurodegeneration due to C9orf72 expansions Investments > €500k United States of America Alzheimer’s disease & other dementias|Motor neurone diseases 2016    

Functions of alpha-Synuclein in Neurotransmitter Release Investments > €500k United States of America Parkinson’s disease & PD-related disorders 2016    

Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Protein Self Assembly into Nanoaggregates Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Argumentation and linked-metadata services for reproducible target validation Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Rehabilitation of speech and language in primary progressive aphasia Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Defining the mechanisms of dipeptide repeat protein toxicity in C9orf72 ALS/FTD Investments > €500k United States of America Alzheimer’s disease & other dementias|Motor neurone diseases 2016    

Effect of Aging on Efficacy of Alzheimer-focused Therapeutic Strategies Investments > €500k United States of America Alzheimer’s disease & other dementias 2016